Despite these limitations, with individual patient data derived from over 4000 subjects with 12 major tumor types treated with immune checkpoint inhibitors, this is the first study to systematically examine the performance of MET mutation as a predictive biomarker in cancer immunotherapy. Here, MET is linked to neoplasm.